Inhalte werden geladen...
From the initial idea to the finished therapy: We bring your medical innovation to life
Lonza is a leading global CDMO offering integrated development and manufacturing services for the pharmaceutical, biotech, and healthcare industries.
Independent B2B performance index (0–100 points). It is calculated mathematically and without subjective influence from four verified pillars: company stability, aggregated feedback from publicly available online sources, documented compliance certifications, and operational transparency.
Headquarters
Muenchensteinerstrasse 38, 4052 Basel, Switzerland
Employees
19000
Founded
1897
Management
Matthew Moorcroft
Lonza is a leading global Contract Development and Manufacturing Organization (CDMO) headquartered in Basel, Switzerland. Since its founding in 1897, the company has grown into one of the largest Western partners for the pharmaceutical, biotech, and healthcare industries. With around 19,000 employees worldwide, Lonza supports clients in translating therapeutic innovations into life-saving treatments. The service portfolio spans the entire product lifecycle: from early-phase discovery support to custom manufacturing of active pharmaceutical ingredients (APIs) and innovative dosage forms. A special focus is placed on biologics, small molecules, cell and gene therapies, and capsule solutions for the pharmaceutical and nutrition industries. In addition, Lonza offers specialized Drug Product Services, which include formulation, analytical development, and sterile filling in state-of-the-art laboratories. As a global industry leader, Lonza adheres to the highest quality and safety standards. The production facilities operate strictly according to GMP (Good Manufacturing Practice) guidelines and are certified under ISO 9001:2015 and HACCP. By combining advanced science, lean manufacturing processes, and global scalability, Lonza enables the rapid and reliable market launch of complex therapies.
Ask about pricing, features, integrations, or comparisons. Our AI assistant can help with up-to-date information.
Lonza recently presented strategic initiatives to strengthen its global market position in biopharmaceuticals and contract manufacturing. Through targeted investments in expanding production capacities in Europe and the US, the company is responding to the growing demand for complex biologics. In addition, innovative drug delivery platforms and new strategic partnerships solidify the service portfolio for global pharmaceutical and biotech clients.
Latest updates
Since no concrete social media mentions or data were provided for Lonza, a well-founded analysis of topics, praise, or criticism is not possible. Without empirical data points, no specific trends or discussions on Reddit and X/Twitter can be reconstructed. To avoid speculation, the evaluation of the current sentiment remains undetermined due to the lack of a database.
Source: Publicly available social media posts (X/Twitter, LinkedIn, Reddit) from the last 12 months. The opinions shown come from users and do not represent BenchTrust's assessment.